J T Holt
Overview
Explore the profile of J T Holt including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
55
Citations
1181
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Obermiller P, Holt J
Methods Mol Med
. 2011 Mar;
35:593-607.
PMID: 21390833
The human breast and ovarian cancer susceptibility gene BRCA1 is a tumorsuppressor gene which is mutated and lost in hereditary breast and ovarian cancer, and has both alleles mutated in...
2.
Malone J, Nelson A, Lieberman R, Anderson S, Holt J
J Pathol
. 2008 Nov;
217(3):380-8.
PMID: 19016568
Disease-associated BRCA2 mutations typically result in protein truncations that delete the phosphorylation-regulated S3291 BRCA2 domain that interacts with Rad51. BRCA2 hereditary breast cancers are usually ER(+), differing from BRCA1 hereditary...
3.
Tait D, Jensen R, Holt J, Johnson D, Gralow J, King M
Breast Dis
. 2005 Feb;
10(1-2):89-98.
PMID: 15687552
As an initial step toward gene therapy for ovarian cancer, we conducted a Phase 1 trial to assess the pharmacokinetics and toxicity of intraperitoneal BRCA1sv retroviral vector therapy. Gene transfer...
4.
Obermiller P, Tait D, Holt J
Breast Cancer Res
. 2001 Mar;
2(1):28-31.
PMID: 11250690
Gene therapy is a therapeutic approach that is designed to correct specific molecular defects that contribute to the cause or progression of cancer. Genes that are mutated or deleted in...
5.
Tait D, Obermiller P, Holt J
Gynecol Oncol
. 2000 Dec;
79(3):471-6.
PMID: 11104622
Objective: The aim of this study was to determine the preclinical stability, toxicity, and efficacy of a second-generation complement-resistant retroviral BRCA1 vector, MFG-BRCA1, for ovarian cancer gene therapy. Methods: MFG-BRCA1...
6.
7.
Tait D, Obermiller P, Hatmaker A, Holt J
Clin Cancer Res
. 1999 Aug;
5(7):1708-14.
PMID: 10430073
Gene therapy with viral vectors has shown some promise in nude mice models and in initial Phase I trials of patients with extensive metastatic cancer. A Phase I clinical trial...
8.
ABBOTT D, Thompson M, Tomlinson G, Jensen R, Holt J
J Biol Chem
. 1999 Jun;
274(26):18808-12.
PMID: 10373498
The breast cancer predisposition genes, BRCA1 and BRCA2, are responsible for the vast majority of hereditary breast cancer. Although BRCA2 functions to help the cell repair double-stranded DNA breaks, the...
9.
ABBOTT D, Holt J
J Biol Chem
. 1999 Jan;
274(5):2732-42.
PMID: 9915804
An increasing body of evidence suggests that mitogen-induced activation of the RAF/ERK signaling pathway is functionally separate from the stress-induced activation of the SEK/JNK/p38 signaling pathway. In general, stress stimuli...
10.
Tait D, Obermiller P, Jensen R, Welcsh P, Dann J, King M, et al.
Clin Cancer Res
. 1998 Nov;
3(11):1959-68.
PMID: 9815585
Gene transfer of BRCA1sv (a normal splice variant of BRCA1) into ovarian cancer cells produces growth inhibition in vitro and tumor suppression in nude mouse xenografts. As an initial step...